share_log

HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Raises Price Target to $6

HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Raises Price Target to $6

HC Wainwright & Co.維持對Akebia Therapeutics的買入,將目標股價上調至6美元
Moomoo 24/7 ·  03/28 12:20

HC Wainwright & Co. analyst Ed Arce maintains Akebia Therapeutics (NASDAQ:AKBA) with a Buy and raises the price target from $5 to $6.

HC Wainwright & Co. 分析師埃德·阿爾塞維持Akebia Therapeutics(納斯達克股票代碼:AKBA)的買入並將目標股價從5美元上調至6美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論